首页> 外文期刊>Saudi Pharmaceutical Journal >Assessment of the risk of QT-interval prolongation associated with potential drug-drug interactions in patients admitted to Intensive Care Units
【24h】

Assessment of the risk of QT-interval prolongation associated with potential drug-drug interactions in patients admitted to Intensive Care Units

机译:评估患者患者收入重症监护单位的患者潜在药物 - 药物相互作用的QT间隔延长的风险

获取原文
           

摘要

Objectives To evaluate the relationship between drug interactions and QT-interval prolongation in patients admitted to a general intensive care unit (ICU). Methods This study was approved by the Institutional Review Board and written informed consent was obtained from all patients. From May 2015 to July 2016, all patients over 18?years-old admitted to the ICU for more than 24?h and in whom the QT-interval on the ECG could be read were prospectively included in this observational, cross-sectional study. All medications administered in the 24?h prior to admission were recorded and the QT-interval was measured upon ICU admission and corrected with Bazzet’s formula (QTc). Drug-drug interactions involving drugs potentially associated with QTc prolongation (DDIQT) were searched and QTc increase associated with pharmacokinetic (PK-DDIQT) and pharmacodynamic (PD-DDIQT) interactions was assessed with multiple regression adjusted by patient varibles. Results The study population consisted of 283 patients, 54.4% males, mean age 57.6?±?16.7?years-old. Forty five (15.9%) patients presented 65 DDIQT with predominance of pharmacodynamic (66.1%). The risk of DDIQT prescription increased with lower systolic blood pressure, in hypokalemia, in non-diabetics and with the number of medications. PK-DDIQT alone did not affect the QTc interval (7.75?ms, 95%CI: –22.4 to 37.9?ms, p?=?0.61), but PD-DDIQT increased QTc by 28.4?ms (95%CI: 9.67 to 47.4?ms, p?=?0.003). Most PD-DDIQT involved metoclopramide with ondansetron or amiodarone, and ondansetron with ciprofloxacin. Conclusions In patients exposed to drugs associated with prolonged QTc in the 24?h prior to ICU admission, pharmacodynamic DDIQT are associated with increased risk of QTc prolongation.
机译:目标旨在评估药物相互作用与QT间间延长的患者患者达到一般密集护理单位(ICU)。方法本研究经机构审查委员会批准,并从所有患者中获得书面知情同意书。从2015年5月到2016年7月,所有超过18名患者的患者超过24岁以上的ICU超过24?H,并且在这个观察到的横断面研究中,可以读取ECG上的QT间隔。记录在24〜H中施用的所有药物记录,并在ICU入院时测量QT间隔,并用Bazzet的公式(QTC)纠正。搜查了涉及可能与QTC延长(DDIQT)有关的药物的药物 - 药物相互作用,并评估与药代动力学(PK-DDIQT)和药效学(PD-DDIQT)相互作用相关的QTC增加,用患者变量调节多元回归。结果研究人群由283名患者,54.4%的男性组成,平均年龄为57.6岁?±16.7?岁。四十五个(15.9%)患者呈现65℃,具有Pharmacocynamic的优势(66.1%)。 DDIQT处方的风险随着较低的收缩压,低钾血症,非糖尿病患者和药物数量增加。单独的PK-DDIQT不影响QTC间隔(7.75?MS,95%CI:-2.4至37.9?MS,P?= 0.61),但PD-DDIQT增加了QTC 28.4?MS(95%CI:9.67 47.4?MS,P?= 0.003)。大多数PD-DDIQT涉及与ondansetron或胺碘酮的甲酰丙酰胺,并用环丙沙星ondansetron。在ICU入院前24〜H延长QTC与延长QTC相关的药物的结论,药效学DDIQT与QTC延长的风险增加有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号